IE810036L - Sustained release compositions - Google Patents
Sustained release compositionsInfo
- Publication number
- IE810036L IE810036L IE810036A IE3681A IE810036L IE 810036 L IE810036 L IE 810036L IE 810036 A IE810036 A IE 810036A IE 3681 A IE3681 A IE 3681A IE 810036 L IE810036 L IE 810036L
- Authority
- IE
- Ireland
- Prior art keywords
- amount
- milligrams
- release controlling
- agent
- controlling agent
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 7
- 239000003814 drug Substances 0.000 abstract 3
- 230000003628 erosive effect Effects 0.000 abstract 3
- 230000001737 promoting effect Effects 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 229960002390 flurbiprofen Drugs 0.000 abstract 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A sustained release pharmaceutical composition in table-t form comprises an effective amount of an orallyactive therapeutic agent, 0.8 to 1. 6% by weight of a release controlling agent and 1.0 to 7.5% by weight of an erosion promoting agent, the relative amounts of the components being such that a criticality factor calculated according to equation I lies in the range 20 to 450. Equation 1 is <IMG> I wherein CF is the criticality factor, CA is the. amount of therapeutic agent per tablet in milligrams divided by the amount of release controlling agent per tablet in milligrams and CS is the amount of erosion promoting agent per tablet in milligrams divided by the amount of release controlling agent per-tablet in milligrams, Suitable therapeutic agents include acetylsalicylic acid, ibuprofen and flurbiprofen. A preferred release controlling agent is cellulose acetate phthalate and a preferred erosion promoting agent is corn starch.
[CA1140466A]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11143080A | 1980-01-11 | 1980-01-11 | |
| US06/194,453 US4308251A (en) | 1980-01-11 | 1980-10-17 | Controlled release formulations of orally-active medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE810036L true IE810036L (en) | 1981-07-11 |
| IE50806B1 IE50806B1 (en) | 1986-07-23 |
Family
ID=26808896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE36/81A IE50806B1 (en) | 1980-01-11 | 1981-01-09 | Pharmaceutical compositions |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS56103110A (en) |
| AT (1) | AT374681B (en) |
| AU (1) | AU542824B2 (en) |
| BE (1) | BE886998A (en) |
| CA (1) | CA1140466A (en) |
| CH (1) | CH646604A5 (en) |
| DE (1) | DE3100191A1 (en) |
| DK (1) | DK6181A (en) |
| ES (2) | ES8205353A1 (en) |
| FI (1) | FI76927C (en) |
| FR (1) | FR2473308B1 (en) |
| GB (1) | GB2067072B (en) |
| GR (1) | GR73843B (en) |
| IE (1) | IE50806B1 (en) |
| IN (1) | IN151913B (en) |
| IT (1) | IT1221041B (en) |
| LU (1) | LU83052A1 (en) |
| NL (1) | NL8100037A (en) |
| NO (1) | NO156153C (en) |
| NZ (1) | NZ195933A (en) |
| SE (1) | SE447450B (en) |
| ZA (1) | ZA81136B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2496082A (en) * | 1947-05-24 | 1950-01-31 | Ashenfelter William | Scaffold structure |
| IT1144911B (en) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN |
| JPS59227817A (en) * | 1983-06-07 | 1984-12-21 | Toyo Jozo Co Ltd | Long-acting bredinin preparation for oral administration |
| JPH0662404B2 (en) * | 1983-06-14 | 1994-08-17 | シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド | Controlled-release naproxen and naproxen sodium tablets |
| ZA836030B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
| ZA836031B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant release rate solid dosage theophylline formulation |
| EP0138216B1 (en) * | 1983-10-14 | 1993-01-07 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release ifn preparation for parenteral administration |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| DE3688188T2 (en) * | 1985-12-27 | 1993-10-14 | Koken Kk | Process for the preparation of a sustained release formulation. |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| CA1316110C (en) * | 1987-02-27 | 1993-04-13 | Eli Lilly And Company | Sustained release matrix formulations |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US5855915A (en) * | 1995-06-30 | 1999-01-05 | Baylor University | Tablets or biologically acceptable implants for long-term antiinflammatory drug release |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
| NL128902C (en) * | 1960-06-06 | |||
| US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
| US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
| US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
| GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
| JPS5411226A (en) * | 1977-06-24 | 1979-01-27 | Shin Etsu Chem Co Ltd | Disintegratable granule |
-
1980
- 1980-12-23 IN IN1418/CAL/80A patent/IN151913B/en unknown
- 1980-12-23 NZ NZ195933A patent/NZ195933A/en unknown
-
1981
- 1981-01-05 AU AU65976/81A patent/AU542824B2/en not_active Ceased
- 1981-01-06 FR FR8100087A patent/FR2473308B1/en not_active Expired
- 1981-01-07 DE DE19813100191 patent/DE3100191A1/en active Granted
- 1981-01-07 NL NL8100037A patent/NL8100037A/en not_active Application Discontinuation
- 1981-01-08 ES ES498369A patent/ES8205353A1/en not_active Expired
- 1981-01-08 GB GB8100522A patent/GB2067072B/en not_active Expired
- 1981-01-08 CH CH9281A patent/CH646604A5/en not_active IP Right Cessation
- 1981-01-08 JP JP157881A patent/JPS56103110A/en active Pending
- 1981-01-08 BE BE0/203426A patent/BE886998A/en unknown
- 1981-01-08 DK DK6181A patent/DK6181A/en not_active Application Discontinuation
- 1981-01-09 FI FI810056A patent/FI76927C/en not_active IP Right Cessation
- 1981-01-09 NO NO810062A patent/NO156153C/en unknown
- 1981-01-09 IT IT47537/81A patent/IT1221041B/en active
- 1981-01-09 SE SE8100104A patent/SE447450B/en not_active IP Right Cessation
- 1981-01-09 CA CA000368219A patent/CA1140466A/en not_active Expired
- 1981-01-09 GR GR63828A patent/GR73843B/el unknown
- 1981-01-09 AT AT0005481A patent/AT374681B/en not_active IP Right Cessation
- 1981-01-09 ZA ZA00810136A patent/ZA81136B/en unknown
- 1981-01-09 IE IE36/81A patent/IE50806B1/en unknown
- 1981-01-09 LU LU83052A patent/LU83052A1/en unknown
-
1982
- 1982-01-29 ES ES509179A patent/ES509179A0/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| SE8100104L (en) | 1981-07-12 |
| SE447450B (en) | 1986-11-17 |
| AU542824B2 (en) | 1985-03-14 |
| DE3100191C2 (en) | 1988-09-01 |
| IE50806B1 (en) | 1986-07-23 |
| IT8147537A0 (en) | 1981-01-09 |
| LU83052A1 (en) | 1982-09-10 |
| GB2067072A (en) | 1981-07-22 |
| ES498369A0 (en) | 1982-06-01 |
| ES8301629A1 (en) | 1982-12-16 |
| CA1140466A (en) | 1983-02-01 |
| FI76927B (en) | 1988-09-30 |
| FI76927C (en) | 1989-01-10 |
| DE3100191A1 (en) | 1981-12-10 |
| AU6597681A (en) | 1981-07-16 |
| NZ195933A (en) | 1982-11-23 |
| AT374681B (en) | 1984-05-25 |
| FR2473308B1 (en) | 1985-07-19 |
| ES8205353A1 (en) | 1982-06-01 |
| NO156153B (en) | 1987-04-27 |
| IN151913B (en) | 1983-09-03 |
| ZA81136B (en) | 1982-01-27 |
| NL8100037A (en) | 1981-08-03 |
| FI810056L (en) | 1981-07-12 |
| JPS56103110A (en) | 1981-08-18 |
| IT1221041B (en) | 1990-06-21 |
| ES509179A0 (en) | 1982-12-16 |
| NO156153C (en) | 1987-08-05 |
| GR73843B (en) | 1984-05-07 |
| NO810062L (en) | 1981-07-13 |
| FR2473308A1 (en) | 1981-07-17 |
| CH646604A5 (en) | 1984-12-14 |
| DK6181A (en) | 1981-07-12 |
| GB2067072B (en) | 1983-08-10 |
| ATA5481A (en) | 1983-10-15 |
| BE886998A (en) | 1981-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE810036L (en) | Sustained release compositions | |
| CA2009890A1 (en) | Valproic acid | |
| JPS55153715A (en) | Prolonged granule of theophylline | |
| IE791172L (en) | Pharmaceutical compositions containing urea | |
| ATE180668T1 (en) | MEDICINAL PRODUCTS CONTAINING S(+)-IBUPROFEN | |
| FR2698788B1 (en) | Effervescent pharmaceutical composition containing ibuprofen and process for its preparation. | |
| IE891414L (en) | Pharmaceutical compositions | |
| IE781032L (en) | Pharmaceutical compositions | |
| TW350772B (en) | Tablets with improved bioavailability of the active material clodronic acid | |
| AU1112395A (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide | |
| GB1353635A (en) | Coating composition for moist surfaces | |
| ES8705763A1 (en) | Pharmaceutical compositions containing gels. | |
| IL65922A0 (en) | Preparation of apovincaminic acid esters,certain novel optically active derivatives thereof and pharmaceutical compositions containing them | |
| IL102949A0 (en) | Substituted mandelic acid derivatives,their preparation and pharmaceutical compositions containing them | |
| DE3160595D1 (en) | Polyprenyl carboxylic acid derivatives, process for the preparation of the same, and pharmaceutical compositions | |
| US3035987A (en) | Method of increasing the water vapor porosity of fat materials | |
| GB1381426A (en) | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents | |
| ATE16100T1 (en) | ESTERS OF 1-METHYL-5-P-TOLUOYLPYRROLYL-2ACETIC ACID WITH ANTI-INFLAMMATORY, MUCOLYTIC AND ANTI-TUSSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| DE3166825D1 (en) | Process for manufacture of a coated acetylsalicylic-acid formulation | |
| GB1388856A (en) | Fibrinolytic activators comprising derivatives of phenyl benzoate | |
| AU645205B2 (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions | |
| JPS56122312A (en) | Hepatic cholesterol-lowering agent (hepatic decholesterolizing agent) | |
| IE34386B1 (en) | Pharmaceutical compositions | |
| NZ226696A (en) | Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt% | |
| FR2499559B1 (en) | NOVEL 2-HYDROXY-5- (2 ', 4'-DIFLUOROPHENYL) -BENZOIC ACID DERIVATIVES, THEIR PREPARATION METHODS, THEIR USE AS PHARMACOLOGICALLY ACTIVE AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |